MX2016010071A - Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos. - Google Patents
Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.Info
- Publication number
- MX2016010071A MX2016010071A MX2016010071A MX2016010071A MX2016010071A MX 2016010071 A MX2016010071 A MX 2016010071A MX 2016010071 A MX2016010071 A MX 2016010071A MX 2016010071 A MX2016010071 A MX 2016010071A MX 2016010071 A MX2016010071 A MX 2016010071A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- vmat2 inhibitor
- antipsychotic drug
- antipsychotic
- vmat2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Se proporcionan nuevos métodos para tratar esquizofrenia y trastorno esquizoafectivo por la administración de composiciones farmacéuticas que comprenden un compuesto antipsicótico y un inhibidor VMAT2 a un sujeto en tal necesidad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461937223P | 2014-02-07 | 2014-02-07 | |
PCT/US2015/014893 WO2015120317A1 (en) | 2014-02-07 | 2015-02-06 | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010071A true MX2016010071A (es) | 2017-04-27 |
Family
ID=52589782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010071A MX2016010071A (es) | 2014-02-07 | 2015-02-06 | Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos. |
Country Status (12)
Country | Link |
---|---|
US (4) | US9782398B2 (es) |
EP (2) | EP4049681A1 (es) |
JP (4) | JP6718376B2 (es) |
KR (1) | KR102328058B1 (es) |
CN (3) | CN113413385A (es) |
AU (1) | AU2015213778B2 (es) |
CA (1) | CA2938581C (es) |
IL (1) | IL247127B (es) |
MX (1) | MX2016010071A (es) |
NZ (2) | NZ723107A (es) |
RU (2) | RU2021128797A (es) |
WO (1) | WO2015120317A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2753740C2 (ru) * | 2014-05-06 | 2021-08-23 | Ньюрокрайн Байосайенсиз, Инк. | Лечение гиперкинетических двигательных расстройств |
KR102586138B1 (ko) * | 2015-02-06 | 2023-10-05 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | [9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법 |
CN115322188A (zh) * | 2015-10-30 | 2022-11-11 | 纽罗克里生物科学有限公司 | Valbenazine盐及其多晶形物 |
CN108925135A (zh) | 2015-12-23 | 2018-11-30 | 纽罗克里生物科学有限公司 | 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法 |
WO2018001335A1 (zh) * | 2016-06-29 | 2018-01-04 | 苏州科睿思制药有限公司 | Nbi-98854的晶型及其制备方法和用途 |
JP2020500875A (ja) * | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
RU2764443C2 (ru) | 2016-12-20 | 2022-01-17 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен |
EP3558275A1 (en) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine |
JP7090151B2 (ja) | 2017-01-27 | 2022-06-23 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 特定のvmat2インヒビターを投与するための方法 |
JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
MX2020002841A (es) | 2017-09-21 | 2020-07-22 | Neurocrine Biosciences Inc | Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma. |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
AU2017435893B2 (en) | 2017-10-10 | 2023-06-29 | Neurocrine Biosciences, Inc | Methods for the administration of certain VMAT2 inhibitors |
EP3733666B1 (en) | 2017-12-26 | 2022-09-21 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof |
EP3789029B1 (en) * | 2018-05-04 | 2024-05-08 | Korea Institute of Radiological & Medical Sciences | Radiation sensitivity enhancing composition containing aripiprazole as active ingredient |
MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
KR20210022656A (ko) | 2018-06-20 | 2021-03-03 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀을 함유하는 경피 치료 시스템 |
WO2020037022A1 (en) | 2018-08-15 | 2020-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
WO2020188551A1 (en) * | 2019-03-20 | 2020-09-24 | Bol Pharma Ltd. | Methods and compositions for treating autism spectrum disorder and associated disorders |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
KR20240027780A (ko) * | 2021-06-30 | 2024-03-04 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 조현병의 부가적 치료에 사용하기 위한 발베나진 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5777697A (en) * | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
JPS57209225A (en) * | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
US5204329A (en) * | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
WO2000024399A1 (en) * | 1998-10-23 | 2000-05-04 | Sepracor Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
ES2318771T3 (es) | 2005-08-06 | 2009-05-01 | Cambridge Laboratories (Ireland) Limited | 3,11b-cis-dihidrotetrabenazinas para el tratamiento de la esquizofrenia y otras psicosis. |
DK2081929T3 (da) * | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
GB2463452A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
ES2652289T3 (es) | 2008-09-18 | 2018-02-01 | Auspex Pharmaceuticals, Inc. | Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2 |
EP2464340A2 (en) * | 2009-08-12 | 2012-06-20 | Valeant International (Barbados) SRL | Pharmaceutical compositions with tetrabenazine |
CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
-
2015
- 2015-02-06 NZ NZ723107A patent/NZ723107A/en unknown
- 2015-02-06 NZ NZ760790A patent/NZ760790A/en unknown
- 2015-02-06 EP EP21216409.9A patent/EP4049681A1/en active Pending
- 2015-02-06 US US15/116,786 patent/US9782398B2/en active Active
- 2015-02-06 CN CN202110257547.XA patent/CN113413385A/zh active Pending
- 2015-02-06 KR KR1020167024297A patent/KR102328058B1/ko active IP Right Grant
- 2015-02-06 AU AU2015213778A patent/AU2015213778B2/en active Active
- 2015-02-06 JP JP2016549493A patent/JP6718376B2/ja active Active
- 2015-02-06 MX MX2016010071A patent/MX2016010071A/es unknown
- 2015-02-06 RU RU2021128797A patent/RU2021128797A/ru unknown
- 2015-02-06 WO PCT/US2015/014893 patent/WO2015120317A1/en active Application Filing
- 2015-02-06 EP EP15706596.2A patent/EP3102239A1/en not_active Withdrawn
- 2015-02-06 CA CA2938581A patent/CA2938581C/en active Active
- 2015-02-06 CN CN201580009498.0A patent/CN106061506A/zh active Pending
- 2015-02-06 RU RU2016135930A patent/RU2757221C2/ru active
- 2015-02-06 CN CN202110257206.2A patent/CN113368110A/zh active Pending
-
2016
- 2016-08-04 IL IL247127A patent/IL247127B/en active IP Right Grant
-
2017
- 2017-09-11 US US15/701,311 patent/US20180085364A1/en not_active Abandoned
-
2019
- 2019-01-16 US US16/248,855 patent/US20190381029A1/en not_active Abandoned
- 2019-05-07 JP JP2019087459A patent/JP2019116515A/ja not_active Withdrawn
-
2020
- 2020-03-13 US US16/817,723 patent/US20200206215A1/en not_active Abandoned
-
2021
- 2021-03-02 JP JP2021032320A patent/JP2021080294A/ja active Pending
-
2023
- 2023-11-17 JP JP2023195803A patent/JP2024003253A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2021128797A (ru) | 2021-11-26 |
US20160339011A1 (en) | 2016-11-24 |
IL247127A0 (en) | 2016-09-29 |
CN113368110A (zh) | 2021-09-10 |
RU2016135930A3 (es) | 2018-10-05 |
IL247127B (en) | 2021-04-29 |
US9782398B2 (en) | 2017-10-10 |
CA2938581C (en) | 2023-02-28 |
NZ723107A (en) | 2022-11-25 |
CN113413385A (zh) | 2021-09-21 |
WO2015120317A1 (en) | 2015-08-13 |
EP4049681A1 (en) | 2022-08-31 |
AU2015213778A1 (en) | 2016-08-18 |
JP6718376B2 (ja) | 2020-07-08 |
KR20160132830A (ko) | 2016-11-21 |
NZ760790A (en) | 2022-11-25 |
JP2017505316A (ja) | 2017-02-16 |
JP2019116515A (ja) | 2019-07-18 |
AU2015213778B2 (en) | 2020-04-23 |
JP2021080294A (ja) | 2021-05-27 |
RU2757221C2 (ru) | 2021-10-12 |
CN106061506A (zh) | 2016-10-26 |
KR102328058B1 (ko) | 2021-11-17 |
EP3102239A1 (en) | 2016-12-14 |
US20180085364A1 (en) | 2018-03-29 |
US20200206215A1 (en) | 2020-07-02 |
JP2024003253A (ja) | 2024-01-11 |
CA2938581A1 (en) | 2015-08-13 |
RU2016135930A (ru) | 2018-03-15 |
US20190381029A1 (en) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ723107A (en) | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof | |
PH12019500176A1 (en) | Heterocyclic compounds and ther uses | |
NZ724691A (en) | Quinoline derivatives as smo inhibitors | |
PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
TW201613872A (en) | IRAK4 inhibiting agents | |
MX2020005181A (es) | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). | |
MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
EP2986291A4 (en) | COMPOUNDS DERIVED FROM 4-PYRIDONE AND USES THEREOF AS INHIBITORS OF HIV INTEGRASE | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
HK1231390A1 (zh) | 用於局部給藥的藥用組合物 | |
DOP2017000058A (es) | Derivados de tetrahidroquinolina como inhibidores del bromodominio | |
EP3200877A4 (en) | Low dose oral pharmaceutical composition of isotretinoin | |
ZA201703764B (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
PT3143032T (pt) | Novos derivados terapêuticos de oxazafosforinas e as suas utilizações terapêuticas | |
EP3100734A4 (en) | Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma |